Results 171 to 180 of about 2,154,176 (393)

A protein kinase C inhibitor, staurosporine, activates phospholipase D via a pertussis toxin-sensitive GTP-binding protein in rabbit peritoneal neutrophils.

, 1992
Yasunori Kanaho, Kozo Takahashi, Urara Tomita, Taroh Iiri, Toshiaki Katada, M Ui, Y Nozawa   +6 more
openalex   +1 more source

Additional file 4 of Quantitative Structure–Mutation–Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction

, 2020
Liang‐Chin Huang, Wayland Yeung, Ye Wang, Huimin Cheng, Aarya Venkat, Sheng Li, Ping Ma, Khaled Rasheed, Natarajan Kannan   +8 more
openalex   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

Pharmacology Of Protein Kinase Inhibitors

Annual Review of Pharmacology and Toxicology, 1992
H, Hidaka, R, Kobayashi
openaire   +3 more sources

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. [PDF]

Cancers (Basel), 2023
Viganò M, La Milia M, Grassini MV, Pugliese N, De Giorgio M, Fagiuoli S.   +5 more
europepmc   +1 more source

Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation [PDF]

, 2008
Barbara Dewaele, Bartosz Wasąg, Jan Cools, Raf Sciot, Hans Prenen, Peter Vandenberghe, Agnieszka Woźniak, Patrick Schöffski, Peter Marynen, Maria Dêbiec‐Rychter   +9 more
openalex   +1 more source

Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14) [PDF]

, 2018
Levonis, Stephan M, Schweiker, Stephanie S, Sherry, Madeleine, Tauber, Amanda   +3 more
core   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Critical analysis of the prescription and evaluation of protein kinase inhibitors for oncology in Germany. [PDF]

Naunyn Schmiedebergs Arch Pharmacol, 2023
Obst CS, Seifert R.
europepmc   +1 more source